Grifols reports real-world Alzheimer’s data for plasma exchange treatment
Grifols has presented real-world data on therapeutic plasma exchange with albumin replacement in 71 people with mild cognitive impairment or Alzheimer’s disease.
The observational study, conducted at Ace Alzheimer Center Barcelona, followed patients for 18 months and assessed cognitive outcomes alongside the safety and feasibility of outpatient treatment.
Patients received up to 21 sessions of therapeutic plasma exchange (TPE), with albumin replacement and peripheral venous access. Across the study, 1,201 sessions were performed.
The results showed that the average Mini-Mental State Examination (MMSE) score declined by 3.1 points over 18 months, equivalent to 2.5 points per year.
Grifols said this was lower than the approximately 3.3-point annual decline reported in natural history studies of Alzheimer’s disease. However, the comparison should be interpreted cautiously because the studies involved different designs and patient populations.
The findings provide information on the practical delivery of outpatient plasma exchange and its safety profile, but do not establish that the procedure slows cognitive decline.
“These real-world data provide insights into how the procedure performs in routine clinical practice and over an extended follow-up period. The observed cognitive and safety outcomes are encouraging and support our efforts to continue generating evidence on the potential of this approach in Alzheimer’s disease,” said Dr Mercè Boada, founder and senior medical advisor of Ace Alzheimer Center Barcelona.
Outpatient treatment and safety
The study evaluated TPE delivered in an outpatient setting using peripheral venous access, rather than relying on central venous access.
Across 1,201 treatment sessions in 71 patients, the procedure showed a favourable safety and tolerability profile, according to the companies.
The findings are relevant to the practical implementation of plasma exchange, which requires repeated treatment sessions. Demonstrating that it can be delivered on an outpatient basis using peripheral access may help inform further assessment of the approach in routine clinical settings.
However, the study was observational and did not include a control group against which to compare the cognitive outcomes. The results therefore cannot demonstrate that the treatment caused the observed rate of decline.
Findings presented at Alzheimer’s meetings
The data are being presented at the 19th Clinical Trials on Alzheimer’s Disease Conference (CTAD) 2026 in Boston and the 78th Annual Meeting of the Spanish Society of Neurology in Seville.
Two presentations at CTAD cover the safety and feasibility of outpatient TPE and the cognitive outcomes observed over the 18-month follow-up period.
Dr Yahveth Cantero-Fortiz, head of the Therapeutic Apheresis Unit at Ace, is also presenting the findings at the Spanish neurology meeting, during a seminar on plasma exchange with albumin replacement in Alzheimer’s disease.
Antonio Páez, VP of the Neuro Innovation Hub at Grifols, said: “These results complement the clinical evidence generated with AMBAR and provide relevant information on the feasibility of plasma exchange with albumin replacement under routine clinical practice conditions. Our goal is to continue advancing scientific knowledge of this approach.”
Building on the AMBAR clinical study
The new findings add to research from the AMBAR programme, which investigates plasma exchange with albumin replacement in people with Alzheimer’s disease.
The earlier AMBAR clinical study, published in 2020, was a randomised controlled trial involving patients with mild to moderate Alzheimer’s disease. Its primary results reported a 61% reduction in disease progression in the treatment group compared with the control group.
Grifols and Ace Alzheimer Center Barcelona jointly develop the programme through the AMBAR Center in Barcelona.
The latest observational study adds evidence about how the procedure can be delivered in a real-world healthcare setting. Further controlled research will be needed to establish whether the cognitive outcomes translate into a meaningful treatment benefit for people with Alzheimer’s disease.




